1. Scrip
  2. >>Business
  3. >>Strategy

Bellicum Weighs Options After Hitting Brakes On CAR-T Program

 
• By Alaric DeArment

An analyst suggested the company might end up selling its technology to a large pharma player, citing AstraZeneca’s $68m buyout of LogicBio in October as a precedent.

Bellicum is weighing options after announcing it would discontinue its two clinical CAR-T programs • Source: Shutterstock

It is unclear what kinds of strategic alternatives Bellicum Phamaceuticals, Inc. is considering now that the company has decided to discontinue its two chimeric antigen receptor T-cell (CAR-T) therapy programs in solid tumors and assess a different path forward. The company moved to end its clinical trial programs due to toxicity as well as limited financial resources, although an analyst suggested its best strategy may be to sell its assets and know-how, pointing to a similar deal that occurred in October.

Bellicum said 14 March that it would discontinue the Phase I/II clinical trials of BPX-601 in metastatic castration-resistant prostate cancer (mCRPC) and BPX-603 in HER2-positive solid tumors

More from Strategy

More from Business

Merck KGaA Braces For Volatility But Does Not Expect Europe To Budge On Pricing

 
• By Andrew McConaghie

Shares are hit as German conglomerate lowers revenue forecast.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Cipla Leadership’s Early Take On Trump’s Pricing EO And Pipeline Progress

 
• By Anju Ghangurde

Cipla's CEO underlines that US generic prices are already “very significantly comparable” with the rest of the world and expects President Donald Trump's executive order on drug pricing to primarily impact branded pharmaceuticals. The company also shared updates on its US pipeline.